Format

Send to

Choose Destination
See comment in PubMed Commons below
Lancet Diabetes Endocrinol. 2014 Mar;2(3):228-35. doi: 10.1016/S2213-8587(13)70192-X. Epub 2013 Dec 19.

Midlife type 2 diabetes and poor glycaemic control as risk factors for cognitive decline in early old age: a post-hoc analysis of the Whitehall II cohort study.

Author information

1
INSERM U1018, Centre for Research in Epidemiology and Population Health, Hôpital Paul Brousse, Villejuif, France; Université Paris Sud 11, Paris, France.
2
INSERM U1018, Centre for Research in Epidemiology and Population Health, Hôpital Paul Brousse, Villejuif, France; Université de Versailles St-Quentin-en-Yvelines, Versailles, France.
3
Departments of Epidemiology and Public Health, University College London, London, UK; First Department of Medicine, Semmelweis University Faculty of Medicine, Budapest, Hungary.
4
INSERM U1018, Centre for Research in Epidemiology and Population Health, Hôpital Paul Brousse, Villejuif, France.
5
Departments of Epidemiology and Public Health, University College London, London, UK.
6
INSERM U1018, Centre for Research in Epidemiology and Population Health, Hôpital Paul Brousse, Villejuif, France; Departments of Epidemiology and Public Health, University College London, London, UK; Centre de Gérontologie, Hôpital Ste Périne, AP-HP, Paris, France; Université de Versailles St-Quentin-en-Yvelines, Versailles, France. Electronic address: archana.singh-manoux@inserm.fr.

Abstract

BACKGROUND:

Type 2 diabetes increases the risk for dementia, but whether it affects cognition before old age is unclear. We investigated whether duration of diabetes in late midlife and poor glycaemic control were associated with accelerated cognitive decline.

METHODS:

5653 participants from the Whitehall II cohort study (median age 54.4 years [IQR 50.3-60.3] at first cognitive assessment), were classified into four groups: normoglycaemia, prediabetes, newly diagnosed diabetes, and known diabetes. Tests of memory, reasoning, phonemic and semantic fluency, and a global score that combined all cognitive tests, were assessed three times over 10 years (1997-99, 2002-04, and 2007-09). Mean HbA1c was used to assess glycaemic control during follow-up. Analyses were adjusted for sociodemographic characteristics, health-related behaviours, and chronic diseases.

FINDINGS:

Compared with normoglycaemic participants, those with known diabetes had a 45% faster decline in memory (10 year difference in decline -0.13 SD, 95% CI -0.26 to -0.00; p=0.046), a 29% faster decline in reasoning (-0.10 SD, -0.19 to -0.01; p=0.026), and a 24% faster decline in the global cognitive score (-0.11 SD, -0.21 to -0.02; p=0.014). Participants with prediabetes or newly diagnosed diabetes had similar rates of decline to those with normoglycaemia. Poorer glycaemic control in participants with known diabetes was associated with a significantly faster decline in memory (-0.12 [-0.22 to -0.01]; p=0.034) and a decline in reasoning that approached significance (-0.07 [-0.15 to 0.00]; p=0.052).

INTERPRETATION:

The risk of accelerated cognitive decline in middle-aged patients with type 2 diabetes is dependent on both disease duration and glycaemic control.

FUNDING:

US National Institutes of Health, UK Medical Research Council.

Comment in

PMID:
24622753
PMCID:
PMC4274502
DOI:
10.1016/S2213-8587(13)70192-X
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science Icon for PubMed Central
    Loading ...
    Support Center